Background-Functional mitral regurgitation (MR) is a common finding in heart failure patients with dilated cardiomyopathy and has important prognostic implications. However, the increased operative risk of these patients may result in low referral or high denial rate for mitral valve surgery. Cardiac resynchronization therapy (CRT) has been shown to have a favorable effect on MR. Aims of this study were to (1) evaluate CRT as a therapeutic option in heart failure patients with functional MR and high operative risk and (2) investigate the effect of MR improvement after CRT on prognosis. Methods and Results-A total of 98 consecutive patients with moderate-severe functional MR and high operative risk
F unctional mitral regurgitation (MR) is a common finding in heart failure patients with ischemic or nonischemic dilated cardiomyopathy. 1, 2 More importantly, the presence of MR has important prognostic implications in these patients. 1, 3 The initial strategy of treating MR is optimization of medical therapy (afterload reduction and treatment of fluid load). However, in many patients significant functional MR persists and surgery may be the final option to reduce the extent of MR. The main surgical technique for treatment of functional MR is restrictive annuloplasty, with or without additional surgical left ventricular (LV) remodeling. In many of the patients, however, the increased operative mortality risk may result in either a low referral or high denial rate for mitral valve surgery. A recent study by Bach et al reported a nonreferral or denial rate for surgery as high as 84% in patients with moderate-to-severe or severe functional MR. 4 Moreover, it is currently unclear whether mitral valve surgery improves prognosis in this specific group of patients. 5 As a result, indications for mitral valve surgery in heart failure patients with functional MR are not well defined by any currently available guideline. 6 
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Conversely, cardiac resynchronization therapy (CRT) has been shown to have a favorable effect on functional MR. There are several studies that have demonstrated a reduction in extent of functional MR after CRT. [7] [8] [9] [10] [11] [12] Most of these studies, however, were performed in patients with only mild-moderate MR, and therefore less is known about the effects of CRT in patients with moderate-severe functional MR. Furthermore, these studies were limited to changes at midterm (6 months) follow-up, and therefore no data exist with regard to the potential beneficial effects of reduction in MR on long-term prognosis. Consequently, the aims of this study were (1) to evaluate the role of CRT as an alternative therapeutic option in heart failure patients with moderatesevere functional MR and high operative risk and (2) to investigate the effect of reduction in severity of MR after CRT on long-term prognosis.
Methods

Patient Population and Data Collection
A total of 98 consecutive patients with moderate-severe functional MR and high operative risk were included. These patients are part of an ongoing registry and were referred for CRT according to the current guidelines. 13 Patient data were prospectively collected in the departmental Cardiology Information System (EPD-Vision, Leiden University Medical Center, Leiden, the Netherlands).
Cause of heart failure was considered ischemic in the presence of significant coronary artery disease (Ն50% stenosis in Ն1 of the major coronary arteries) and/or a history of myocardial infarction or prior revascularization. The protocol was as follows: In all patients, clinical status was assessed before implantation and at 6 months follow-up. Extensive echocardiography was performed at baseline and repeated 6 months after CRT to (1) quantify LV volumes and function and (2) evaluate the severity of MR. After the 6-month follow-up, patients were scheduled for regular visits to the outpatient clinic.
Clinical Evaluation
In all patients, evaluation of heart failure symptoms according to the New York Heart Association (NYHA) classification was performed. Assessment of quality of life was performed using the Minnesota Living with Heart Failure Questionnaire (high scores indicating poor quality of life), 14 and when possible exercise capacity was measured using the 6-minute walk test. 15 In addition, operative risk was assessed by means of the logistic Euroscore. 16 Estimated glomerular filtration rate (eGFR) was calculated using the standard formula by Cockcroft and Gault and expressed in mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 . 17 Finally, outcome data were collected by chart review, device interrogation, and telephone contact. Primary end point during long-term follow-up was death from any cause.
Echocardiography
All patients underwent echocardiography in the left lateral decubitus position before and 6 months after CRT implantation. Imaging was performed using a commercially available echocardiographic system (VIVID 7, General Electric Vingmed Ultrasound, Milwaukee, WI). Images were obtained using a 3.5 MHz transducer at a depth of 16 cm in the parasternal and apical (2-, 3-, and 4-chamber) views. All images were recorded digitally in cine-loop format and analyzed offline with commercial software (EchoPac 108.1.5, General Electric Vingmed Ultrasound).
Left Ventricular Volumes and Function Analysis
LV end-diastolic and LV end-systolic volumes (LVEDV and LVESV, respectively) were determined from the conventional apical 2-and 4-chamber views, and LV ejection fraction (LVEF) was calculated using the biplane Simpson technique. 18 Volumetric response to CRT was defined as a reduction Ն15% in LVESV at 6 months follow-up. 19 
Assessment of Mitral Regurgitation Severity
Following current guidelines, 20, 21 we assessed the severity of MR using a multiparametric approach, which combined the following measurements: (1) vena contracta width (VCW), measured as the narrowest portion of the MR color Doppler jet in a zoomed optimized parasternal long-axis view or in the apical 4-chamber view; (2) the ratio of the jet area to the left atrium (LA) area measured by planimetry in the 4-chamber view; (3) the effective regurgitant orifice area (EROA) calculated with the proximal isovelocity surface area method. The color Doppler images were acquired using a Nyquist limit of 30 to 60 cm/second and a color gain that just eliminates random color speckle from nonmoving regions. Severity of MR was defined using a multiparametric approach according to current guidelines 21 and graded on a 4-point scale: mildϭ1ϩ, moderateϭ2ϩ, moderate-severeϭ3ϩ, and severeϭ4ϩ. Improvement in MR was defined as a reduction Ն1 grade 6 months after CRT. In addition, as a measure of mitral valve deformation, valvular tenting area was measured from the parasternal long-axis view at midsystole as the area enclosed between the annular plane and mitral leaflets. Left atrium volumes were measured form the 2-and 4-chamber views using the biplane Simpson technique. Finally, estimated systolic pulmonary artery pressure (SPAP) was derived from the right ventricular to right atrial pressure gradient or tricuspid regurgitant jet gradient and calculated with the modified Bernoulli equation. 22
Statistical Analysis
Continuous data are presented as meanϮSD, and dichotomous data are presented as n (%). Comparison of data at baseline and 6-month follow-up was performed with the paired-samples t test. Comparison of data between patient groups was performed using the independent-samples t test for continuous data. The Fisher exact tests or 2 tests were used as appropriate to compare dichotomous data. Analysis of variance for repeated measurements, including interaction between group and time, was applied for comparison of data between patient groups at baseline and 6 months follow-up. The event-free survival of patients was evaluated with the Kaplan-Meier 
Results
Patient Characteristics
Baseline characteristics of the patient population are presented in Table 1 . The majority of patients were men (74%), and the underlying cause of heart failure was ischemic cardiomyopathy in 62 patients (63% 
Clinical and Left Ventricular Functional Changes After 6 Months of Cardiac Resynchronization Therapy
At 6-month follow-up, the mean NYHA class improved from 3.1Ϯ0.3 to 2.1Ϯ0.7 (PϽ0.001). In addition, the quality of life score decreased from 38Ϯ18 to 24Ϯ17 (PϽ0.001) whereas distance covered in the 6-minute walk test increased from 283Ϯ109 m to 368Ϯ120 m (PϽ0.001). Significant LV reverse remodeling was observed at 6-month follow-up, as shown by a decrease in LVEDV from 261Ϯ88 mL at baseline to 233Ϯ81 mL at follow-up and a decrease in LVESV from 205Ϯ81 mL to 166Ϯ72 mL (both PϽ0.001). Furthermore, an increase in LVEF from 23Ϯ7% at baseline to 30Ϯ9% at follow-up was noted (PϽ0.001). Volumetric response to CRT (reduction Ն15% in LVESV at 6-month follow-up) was observed in 54 patients (55%).
Changes in Mitral Regurgitation Severity After 6 Months of Cardiac Resynchronization Therapy
Severity of MR improved significantly according to all evaluated parameters (Figure 1) . The VCW decreased from 0.74Ϯ0.15 cm at baseline to 0.59Ϯ0.21 cm at follow-up (PϽ0.001) whereas the EROA decreased from 0.51Ϯ0.16 cm 2 to 0.43Ϯ0.18 cm 2 (Pϭ0.001). Tenting area decreased from 7.2Ϯ2.0 cm 2 at baseline to 6.2Ϯ2.0 cm 2 at follow-up (PϽ0.001), and the LA volume decreased from 103Ϯ38 mL to 91Ϯ32 mL (PϽ0.001). Finally, the regurgitant jet area ratio decreased from 51Ϯ14% at baseline to 41Ϯ18% at follow-up (PϽ0.001) and mean SPAP decreased from 35Ϯ10 mm Hg to 31Ϯ10 mm Hg (Pϭ0.001). An example of significant improvement in severity of MR is displayed in Figure 2 .
Mitral Regurgitation Improvers Versus Mitral Regurgitation Nonimprovers After Cardiac Resynchronization Therapy
At 6-month follow-up, MR improvement (reduction Ն1 grade of MR as previously described) was noted in 42 patients (49%). These patients were therefore considered MR improvers. Baseline clinical characteristics were comparable between MR improvers and MR nonimprovers. However, ischemic cause of heart failure was more frequently observed among MR nonimprovers ( Table 2 ). In addition, MR improvers had slightly less symptomatic heart failure (according to the NYHA functional class).
Comparison of clinical and echocardiographic data between MR improvers and nonimprovers, both at baseline and 6-month follow-up, is displayed in Table 3 . At 6-month follow-up, both MR improvers and MR nonimprovers had an improvement in clinical characteristics. However, these improvements were more pronounced in MR improvers. All baseline echocardiographic parameters were comparable between MR improvers and nonimprovers. At 6-month followup, reductions in LV volumes and an increase in LVEF were observed in both groups. Of note, 39 MR improvers (93%) also had significant LV volumetric response, versus only 15 patients (35%) in the MR nonimprovers group (PϽ0.001). By definition, MR improvers had a significant decrease in MR 
Improvement in Mitral Regurgitation and Long-Term Prognosis After Cardiac Resynchronization Therapy
To evaluate whether improvement in MR has prognostic importance after CRT, MR improvement was investigated in relation to all-cause mortality during long-term follow-up (median 32 [range 6.0 to 116] months). During this follow-up period, 34 patients (40%) died. Survival was superior in MR improvers compared with MR nonimprovers (log rank PϽ0.001; Figure 3 ). Respective 1-and 2-year survival rates were 97% and 92% in MR improvers compared with 88% and 67% in MR nonimprovers (log rank Pϭ0.117 for comparison at 1-year follow-up and log rank Pϭ0.013 at 2-year follow-up). Additionally, MR improvement was tested as an independent predictor for all-cause mortality using a multivariate Cox proportional hazards model. In univariate analysis, MR improvement reached a crude hazard ratio (HR) of 0.21 (95% confidence interval 0.09 to 0.49, PϽ0.001). After correction for other significant variables in the univariate analysis, MR improvement remained a strong independent predictor of survival after CRT, with a corrected HR of 0.35 (95% confidence interval 0.13 to 0.94, Pϭ0.043, Table 4 ).
Discussion
The findings of the present study can be summarized as follows: (1) CRT reduces severity of MR at 6-month follow-up in heart failure patients with moderate-severe functional MR and at high risk for mitral valve surgery, and (2) improvement in MR results in superior survival during long-term follow-up.
Functional Mitral Regurgitation in Heart Failure
In heart failure patients with impaired LV systolic function, MR is a frequent finding. It is estimated that nearly half of these patients have some degree of MR, and in Ϸ30% of these cases, extent of MR can be graded as moderate or severe. 1, 3, 23 In most patients, a structurally normal mitral valve is present, but the regurgitation is secondary to changes in LV geometry caused by LV remodeling (dilatation). This specific type of MR is referred to as functional MR. 6, 23 There have been several studies that have evaluated the effect of mitral valve surgery in patients with heart failure and functional MR. 24 -26 Wu et al studied 682 patients with significant MR and LV systolic dysfunction. 24 Out of these 682 patients, 419 were considered candidates for surgical correction. Surprisingly, only 126 of these patients (30%) eventually underwent mitral valve repair. Mentioned reasons for nonreferral or denial for surgery included cardiogenic shock, renal failure, significant valvular lesion other than MR, and the fact that patients were felt to be too weak to undergo surgery after evaluation by cardiac surgeon or cardiologist. Other reasons included the coexistence of conditions that increased the risk of cardiac surgery. During long-term follow-up, 112 patients (38%) who were not referred to or were denied for surgery died versus 61 of those who had undergone mitral valve surgery (48%; PϭNS). It was therefore concluded that there was no significant survival benefit in the surgical group. The finding that 70% of patients were either not referred or denied for mitral valve surgery was confirmed by another recent study from the same group. 4
Effects of Cardiac Resynchronization Therapy on Functional Mitral Regurgitation
Contrasting with the above-mentioned results on surgery for functional MR, previous studies on the effects of CRT have not only demonstrated improved survival 27 but also a significant reduction in extent of functional MR after CRT. [7] [8] [9] [10] [11] [12] Most of the studies on changes in MR after CRT were single-center studies with limited numbers of patients. Nonetheless, results among these studies are consistent, and several explanations for improvement in MR, including the immediate effect of resynchronization and improvement of LV contraction (inducing synchronized mechanical activation of papillary muscle insertion sites), 8, 10 and the more delayed effect of favorable changes in mitral valve geometry (LV reverse remodeling) 10, 11 have been proposed. Moreover, in the Cardiac Resynchronisation in Heart Failure (CARE-HF) trial, which randomized 813 patients to receive either biventricular pacing in addition to optimized medical therapy or optimized medical therapy alone, there was a significantly greater reduction in MR (measured by the regurgitant jet area ratio) in patients who received CRT compared with patients on optimized medical therapy alone 3 months after CRT (difference in means 5.1%, PϽ0.001). 27 Finally, pooled data from several major studies including 357 patients implanted with a CRT device, with a follow-up of at least 6 months, showed a reduction in functional MR (measured by the regurgitant jet area) of 30% to 40% after CRT. 28 The above-mentioned results clearly demonstrate the beneficial effects of CRT on functional MR. Several contributing factors to nonresponse to CRT, such as inappropriate LV lead positioning and, in patients with ischemic cardiomyopathy, the extent and location of scar tissue, have been previously reported. 29 -32 These factors might also have a significant effect on the changes in MR after CRT. Positioning the LV pacing lead at the optimal site (latest activated myocardial segment) may improve MR during CRT by any of the 2 mechanisms described above (synchronized mechanical activation of papillary muscle insertion sites and LV reverse remodeling during follow-up). Conversely, the presence of significant scar tissue may limit the extent of LV reverse remodeling after CRT and therefore also prevent the improvement in MR. In addition, positioning the LV lead at the level of a nonviable myocardial segment may significantly hamper the beneficial effect of CRT on LV remodeling and MR. Specific studies are needed to further explore the relationship between these different factors and the improvement of MR after CRT.
Improvement in Mitral Regurgitation Versus Long-Term Follow-Up
In the current study, eGFR, LVESV response, and MR improvement were all independently associated with improved long-term outcome (survival) after CRT. Previously, several studies have shown that a (significant) reduction in van Bommel et al CRT in Moderate-Severe MR LVESV at 6 months follow-up resulted in superior long-term survival after CRT. 33, 34 Yu et al reported that patients with a reduction in LVESV Ն10% after CRT had significantly better survival compared to patients with LVESV reduction Ͻ10% whereas a more recent study by Ypenburg et al even related the extent of LV reverse remodeling to long-term prognosis after CRT. These observations are confirmed by the current findings, where patients with a volumetric response after CRT (defined as a reduction Ն15% in LVESV at 6 months follow-up) had significantly better long-term prognosis. A novel finding in the current study is that in addition to this significant LV reverse remodeling, a reduction of Ն1 grade of MR 6 months after CRT (MR improvement) also resulted in superior survival during long-term follow-up (log rank PϽ0.001). Specifically, the 1-and 2-year survival rates were 97% and 92% in MR improvers compared with 88% and 67% in MR nonimprovers. More importantly, this beneficial survival effect of MR improvement was independent of other characteristics, including LVESV response at 6 months follow-up. This is the first study to establish a relation between improvement in MR at 6 months follow-up and superior survival during long-term follow-up after CRT. Possible explanations for this improved survival can be the further decrease in afterload induced by the reduction in MR or the interplay between reduction in MR and LV reverse remodeling. However, the survival benefit of MR improvement was independent of LVESV response at 6 months follow-up.
Conclusions
The observations in the present study indicate that CRT reduces the severity of MR at 6-month follow-up in heart failure patients with moderate-severe functional MR who are at high risk for mitral valve surgery. Applying CRT in this specific group may yield a new therapeutic option for MR. More importantly, patients with a reduction Ն1 grade of MR (MR improvers) had superior survival during long-term follow-up. This implicates a sustained survival benefit of CRT for heart failure patients with moderate-severe functional MR.
